Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastoma

Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastoma

Two novel hybrid compounds, CON1 and CON2, have been developed by combining sclareol (SC) and doxorubicin (DOX) into a single molecular entity. These hybrid compounds have a 1:1 molar ratio of covalently linked SC and DOX. They have demonstrated promising anticancer properties, especially in gliobla...

Full description

Bibliographic Details
Main Authors: Ana Stepanović, Nataša Terzić Jovanović, Aleksandra Korać, Mario Zlatović, Igor Nikolić, Igor Opsenica, Milica Pešić
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:Biomedicine & Pharmacotherapy
Subjects:
hybrid compounds
sclareol, doxorubicin
glioblastoma
cancer multidrug resistance
nanoparticles
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332224003809

Internet

http://www.sciencedirect.com/science/article/pii/S0753332224003809

Similar Items